Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

This study determined the effects of a novel combination of vitamin D and probiotic on metabolic and clinical symptoms in chronic schizophrenia.

This study was retrospectively registered in the Iranian website ( www.irct.ir ) for clinical trials registration ( http://www.irct.ir: IRCT2017072333551N2). 07-31-2017 2.

Who Took Part

The abstract describes 60 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Antioxidants, Dietary Supplements, Insulin Resistance, Iran, Malondialdehyde, Probiotics and Schizophrenia.

The authors tagged it with the keywords Metabolic status, Probiotic supplementation and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 60 patients.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (BMC psychiatry), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.